OV-329 is under clinical development by Ovid Therapeutics and currently in Phase I for Partial Seizure. According to GlobalData, Phase I drugs for Partial Seizure have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OV-329’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OV-329 overview

Small molecule is under development for the treatment of resistant orphan epilepsy  associated with tuberous sclerosis complex, focal seizures (partial seizure), infantile spasms and drug addiction. The drug candidate is administered through oral route. It acts by targeting GABA aminotransferase.

Ovid Therapeutics overview

Ovid Therapeutics is biopharmaceutical company that focused on the drug discovery and development for epilepsies and rare CNS disorders. The company product pipeline includes OV329 for the treatment of treatment of seizures, OV350 for the treatment of treating epilepsies. It also provides OV882, OV815, OV825 and Soticlestat. Ovid Therapeutics carries out the drug discovery and development. The company works in partnership with patients, clinicians and scientists, foundations, academic centers, regulatory agencies, and companies. It collaborates with Lundbeck and Angelman Syndrome foundations. Ovid Therapeutics is headquartered in New York, the US.

For a complete picture of OV-329’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.